Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jordyn Hofer

Nurse Practitioner, Family Sioux Falls, SD Nurse Practitioner

NPI 1114698875 CMS profile 10716781

3401 W 49Th St, Sioux Falls, SD 57106

Open in the dashboard

General payments

$3,455

230 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jordyn Hofer of Sioux Falls, SD is reported in the CMS Open Payments database as having received $3,455 across 230 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $962 61
2024 General $873 60
2023 General $1,156 78
2022 General $426 28
2021 General $38 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jordyn Hofer
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Jordyn Hofer were reported at $962. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Jordyn Hofer Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $38 $124 $35–$379 $132
2022 $426 $141 $44–$430 $149
2023 $1,156 $154 $49–$476 $160
2024 $873 $165 $51–$504 $164
2025 $962 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $590 36 payments
  2. Novo Nordisk Inc $491 37 payments
  3. Pfizer Inc. $367 30 payments
  4. Lilly USA, LLC $315 22 payments
  5. Amgen Inc. $202 13 payments
  6. Astellas Pharma US Inc $149 10 payments
  7. Daiichi Sankyo Inc. $135 8 payments
  8. GlaxoSmithKline, LLC. $116 8 payments
  9. Mylan Specialty L.P. $114 7 payments
  10. AstraZeneca Pharmaceuticals LP $74 5 payments
  11. Other $902 54 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,455 230 payments
Products named General payments · program years 2021–2025
  1. Ozempic $405 30 payments
  2. RYBELSUS $390 29 payments
  3. UBRELVY $293 15 payments
  4. QULIPTA $271 13 payments
  5. MOUNJARO $232 14 payments
  6. EVENITY $177 11 payments
  7. COMIRNATY $176 12 payments
  8. YUPELRI $160 9 payments
  9. VRAYLAR $145 11 payments
  10. INJECTAFER $135 8 payments
  11. Other $2,650 189 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 63 drugs

Part D claims

1,925

Median for Nurse Practitioner: 389

Drug cost

$145,489

Median for Nurse Practitioner: $21,885

Branded share of claims

17.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 20 $27,502
Trulicity Dulaglutide Brand 15 $20,285
Mounjaro Tirzepatide Brand 16 $18,615
Xarelto Rivaroxaban Brand 14 $17,172
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 17 $13,210
Glyxambi Empagliflozin/Linagliptin Brand 21 $11,966
Farxiga Dapagliflozin Propanediol Brand 14 $10,916
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 12 $3,807
Rosuvastatin Calcium Generic 93 $2,239
Tizanidine Hcl Generic 14 $1,858

The 10 drugs with the highest cost, of 63 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$3,783

Medicare's payments for the services billed

Medicare patients

77

Average age 71

Services billed

105

51 women, 26 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 48%
Depression 31%
Diabetes 26%
Ischemic heart disease 26%
Chronic kidney disease 26%
COPD 23%
Osteoporosis 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $80
$80 — —
RYBELSUS
  • Novo Nordisk Inc $74
$74 — —
Ozempic
  • Novo Nordisk Inc $74
$74 20 —
Veozah
  • Astellas Pharma US Inc $63
$63 — —
MOUNJARO
  • Lilly USA, LLC $60
$60 16 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

230 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in South Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record